Nowemapa 8, 2020/Kolepa Lapaʻau, Ke Kulanui ʻo Tibet/Pharmaceutical Biology

Text/Wu Tingyao

Hiki i nā maʻi maʻi maʻi ke laweʻO Ganoderma lucidumʻoiai e loaʻa ana ka lāʻau lapaʻau?Manaʻolana e hiki i kēia hōʻike noiʻi ke hāʻawi i kekahi mau pane.

ʻO Gefitinib (GEF) kekahi o nā lāʻau lapaʻau koʻikoʻi nui no ka mālama ʻana i ka maʻi maʻi maʻi maʻi a me ka metastatic non-small cell lung (me ka lung adenocarcinoma, squamous cell lung cancer, a me ka maʻi maʻi pūpū nui), e lawe mai ana i ka manaʻolana i nā poʻe maʻi. ke ola nei i ka pouli.Akā, ʻaʻole e ʻā mau ke kukui ma ka puka o ka tunnel, no ka mea, e ulu ana ke kū'ē i ka lāʻau ma hope o ʻumi a ʻumikumamāono mahina o ka mālama ʻana.

No laila, inā hiki iā mākou ke hopu i ka manawa e hoʻomaikaʻi ai i ka hopena curative o GEF, e hoʻāʻo e mālama i ka maʻi kanesa maʻi i kahi kūlana i hiki ke hoʻomalu a mālama maikaʻi ʻia a i ʻole e hōʻemi i nā hopena ʻaoʻao o nā lāʻau lapaʻau i hiki i nā maʻi ke loaʻa i kahi kūlana kino maikaʻi aʻe e hoʻoponopono ai. ma'i 'a'ai, aia paha he manawa kūpono e ho'omālamalama a 'oi aku ka mālamalama o ke ola.

ʻO nā mea noiʻi mai ke Keʻena Oncology o Yantai Hospital o Traditional Chinese Medicine a me ka Medical College of Tibet University i hoʻopuka pū ʻia i kahi hōʻike noiʻi ma "Pharmaceutical Biology" i ka hopena o 2020 i hōʻike ʻia ma o nā hoʻokolohua holoholona no ka adenocarcinoma māmā maʻamau i ka liʻiliʻi ʻole. ka ma'i 'a'ai ma'i pūpū, ka ho'ohana hui 'ana oGanodermalucidumHiki i nā triterpenoids (GLTs) a me GEF ke hoʻopaʻa maikaʻi i ka ulu ʻana o ka maʻi maʻi a hōʻemi i nā hopena ʻaoʻao o nā lāʻau lapaʻau, e hāʻawi ana i kahi hoʻolālā hou kūpono e noʻonoʻo ai no nā hoʻolālā lapaʻau pili.

Ua hoʻokomo mua nā mea noiʻi i nā laina cell alveolar adenocarcinoma (A549 cell lines) ma lalo o ka ʻili o nā ʻiole me nā ʻōnaehana pale ʻole.Ma hope o nā anawaena o nā ʻōpū subcutaneous ma kahi o 6-8 mm, hoʻomaka lākou e hānaiʻO Ganoderma lucidumtriterpenoids (GLT, 1 g / kg / lā), gefitinib (GEF, 15 mg / kg / lā) a i ʻole ka hui pū ʻana o nā mea ʻelua no nā lā 14, a ua pau ka hoʻokolohua ma ka lā 15th.Ua ʻike ʻia:

(1) Hoʻomaikaʻi i ka ulu ʻana o ka maʻi tumora

Hiki i nā GLT a me GEF ke kāohi i ka ulu ʻana o nā ʻōpū adenocarcinoma māmā, akā ʻoi aku ka maikaʻi o ka hui ʻana o nā mea ʻelua (Figure 1 ~ 3).

Kiʻi 1 Nā ʻiole i lawe ʻia mai loko mai o nā ʻiole adenocarcinoma māmā ma ka hopena o ka hoʻokolohua

Kiʻi 2 Nā hoʻololi i ka ulu ʻana o nā ʻiole adenocarcinoma māmā i ka wā o ka hoʻokolohua

Kiʻi 3 ʻAi ʻole ka ulu ʻana o ka tumora o nā ʻiole adenocarcinoma māmā ma o nā ʻano lapaʻau like ʻole

2) E hoʻoikaika i ka pale ʻana i ka angiogenesis tumor a me ka hoʻolaha ʻana i ka apoptosis cell cancer

Pono nā ʻōpū e hana i nā moku hou i mea e ulu mau ai.No laila, ua lilo ka mānoanoa o nā microvessels i loko o nā ʻiʻo ʻiʻo i mea koʻikoʻi i ka ulu maʻalahi o nā ʻōpū.Hōʻike ka Kiʻi 4 (A) i ka māhele ʻana o nā moku liʻiliʻi i loko o nā ʻāpana ʻiʻo tumora o kēlā me kēia hui.Hōʻike ka Figure 4 (B) i ka hui pū ʻana o nā GLT a me GEF i ʻoi aku ka maikaʻi o ka hopena paʻa ma mua o nā mea ʻelua wale nō.

Kiʻi 4 Nā ʻāpana ʻiʻo tumora a me ka nui o nā ʻiole adenocarcinoma māmā

I nā huaʻōlelo ʻē aʻe, hiki i ka hui ʻana o GLT a me GEF ke kāohi i nā ʻiʻo ʻokoʻa hou aʻe mai ka loaʻa ʻana o nā meaʻai a paʻakikī i ka ulu ʻana o nā ʻōpū.ʻO kēia kaʻina hana mai ka hoʻoponopono ikaika ʻana o ka ʻōlelo gene pili a me ka huna ʻana o ka protein i loko o nā ʻiʻo tumora, me ka pale ʻana i ka "vascular endothelial growth factor receptor 2 (VEGFR2)" a me ka paipai ʻana i ka hana ʻana o "Angiostatin" a me "endostatin".

Eia kekahi, ua nānā nā mea noiʻi i nā ʻāpana ʻiʻo tumora o kēlā me kēia hui o nā ʻiole ma lalo o ka hana hui ʻana o GLTs a me GEF, e hoʻonui nui ka huna ʻana o ka protein (Bax) e hāpai ana i ka apoptosis cell cancer aʻo ka huna ʻana o ka protein (Bcl- 2) e hoʻemi ana ka mea e pale ai i ka apoptosis o nā maʻi maʻi.ʻO nā pūnaʻi adenocarcinoma māmā e hoʻolalelale i ka hoʻomohala ʻana i ke ala o ka apoptosis i kēia ikaika hoʻohui a emi.

(3) E ho'ēmi i ka hopena o nā lāʻau lapaʻau

ʻO nāʻiole adenocarcinoma māmā i mālama ʻia me GEF ka nui o ke kaumaha o ke kaumaha;ma kekahi ʻaoʻao, hiki i ka hui pū ʻana o GLT a me GEF ke mālama maikaʻi i ke kino o ka māmā adenocarcinoma mice ── kokoke loa i nā ʻiole maʻamau (hui mana maʻamau) (Figure 5).

Eia kekahi, ʻo nā ʻiole adenocarcinoma māmā i mālama ʻia me GEF i hōʻike i ka hopohopo, ka luhi, ka hiamoe, ka emi ʻana o ka hana, ka emi ʻana o ka makemake a me ka ʻili ʻili.Eia naʻe, ʻoi aku ka maʻalahi o kēia mau kūlana a ʻaʻole maopopo i ka hui i mālama ʻia me ka hui pū ʻana o GLT a me GEF.ʻIke loa, hiki i nā GLT ke hoʻoponopono i nā hopena ʻino i hana ʻia e GEF.

Kiʻi 5 Nā pihi o nā moʻolelo kaumaha a me nā loli i nā ʻiole adenocarcinoma māmā i ka wā o ka hoʻokolohua

(4) Ka palekana o nā GLT

I mea e loiloi ai i ka palekana o nā GLT, ua hoʻohana nā mea noiʻi i nā laina cell alveolar epithelial cell maʻamau BEAS-2B a me nā laina cell adenocarcinoma alveolar kanaka A549 i hoʻohana ʻia i nā hoʻokolohua holoholona me nā GLT in vitro no 48 mau hola.

Hōʻike ʻia nā hopena ma ke Kiʻi 6. I ka wā i kāohi ai nā GLT (concentrations o 2.5 a me 5 mg/L) i ke ola ola o nā pūnana adenocarcinoma lung i 80-60%, ola mau nā cell maʻamau;ʻoiai ma nā haʻahaʻa kiʻekiʻe, ʻokoʻa ka mālama ʻana o nā GLT i nā sela maʻi maʻi a me nā mea maʻamau, a ʻoi aku ka nui o kēia ʻokoʻa ma mua o GEF (Figure 7).

Kiʻi 6 ʻO ka hopena pale o nā GLT i ka ulu ʻana o ke kelepona

Kiʻi 7 ʻO ka hopena pale o ka gefitinib i ka ulu ʻana o ke kelepona

Wahi a ka noiʻi noiʻi, ʻo nā waiwai IC50 o GLTs ma 48 mau hola o ka mālama ʻana no nā laina kelepona A549 he 14.38 ± 0.29 mg/L ʻoiai ua hōʻike ʻo GLT i kahi hopena cytotoxic ʻoi aku ka ikaika ma ka laina kelepona BEAS-2B me kahi waiwai IC50 o 78.62. ± 2.53 mg/L, ʻo ia hoʻi, inā make nā GLT i nā maʻi maʻi maʻi, hiki iā lākou ke mālama i kahi kiʻekiʻe o ka palekana i nā cell maʻamau.

Hele pū nā GLT a me ka lāʻau lapaʻau i manaʻo ʻia, e ʻoi aku ka maikaʻi o ka mālama ʻana.

Ua hōʻike mai kēia hōʻike noiʻi iā mākou:

Ma lalo o nā kūlana hoʻokolohua like, ʻaʻole i like ka hopena o ka hoʻohana waha ʻana i nā GLT i nā maʻi maʻi adenocarcinoma māmā kanaka e like me GEF, akā ʻaʻohe hopena ʻaoʻao o GEF i nā GLT.

Ke hana pū nā GLT a me GEF, ʻaʻole hiki iā lākou ke hoʻonui wale i ka hopena paʻa i ka ulu ʻana o ka maʻi tumora akā e hōʻemi pū i nā hopena o gefitinib ma ke kaumaha, ka ʻuhane, ka ikaika, ka ʻai a me ka ʻili.ʻO kēia ka mea i kapa ʻia "ka hoʻonui ʻana i ka pono a me ka hoʻohaʻahaʻa ʻana i ka toxicity".

ʻO ke kumu e hiki ai i nā GLT ke hoʻomaikaʻi i ka pale ʻana o GEF i nā ʻōpū adenocarcinoma māmā e pili ana i ka "inhibiting tumor angiogenesis" a me ka "promoting cancer cell apoptosis".

I mea e loiloi ai i ka maʻi maʻi kanaka i loko o nā holoholona, ​​ua hoʻohana nā mea noiʻi i nā ʻiole me nā ʻōnaehana pale kīnā ʻole (i hiki ai i nā cell cancer ke ulu i nā ʻano like ʻole).No laila, ʻo nā hopena ka hopena o nā GLT a me GEF ponoʻī i nā pūnaeho maʻi maʻi.

Eia nō naʻe, i ka hoʻohana maoli ʻana i ka anti-cancer, pono e komo ka hana o ka ʻōnaehana pale.No laila, ma kahi o GLT a me GEF, inā hoʻohui ʻia ka "immunity maikaʻi", e ʻoi aku ka maikaʻi o nā hopena?

ʻAʻole i hōʻike nui nā mea noiʻi i nā GLT i hoʻohana ʻia i ka hoʻokolohua, akā e like me ka wehewehe ʻana o ka pepa, pono ia e lilo i mea ʻala o nā ʻano GLT.Akā ʻo ka nui o ka nui o ka nui o hoʻokahi gram no ke kilokika o ke kaumaha o ke kino i nā ʻiole.Hōʻike kēia iā mākou e koi ana nā noi kūpono i ka nui o ka nui e pono ai.Ma ka ʻaoʻao ʻē aʻe, hāʻawi ia iā mākou i ka manaʻolana i ka wā e hiki mai ana e hiki ke loaʻa i nā mea koʻikoʻi e hiki ke hana maikaʻi a maikaʻi paha ma nā haʻahaʻa haʻahaʻa.

Ma kekahi hihia, ma ka liʻiliʻi loa ua hōʻike kēia noiʻi ʻaʻole nā ​​triterpenoids mai Ganoderma lucidum wale nō ʻaʻole e keʻakeʻa i ka mālama ʻana i nā lāʻau lapaʻau maʻamau i hoʻohana ʻia akā he hopena maikaʻi nō hoʻi o ka "hoʻonui ʻana i ka pono a me ka hoʻohaʻahaʻa ʻana i nā mea make" e pili ana i ka palekana nui.
ʻO ka ʻohi ʻana i loko o ke ala ʻeleʻele e pono ai ke kukui kukui e alakaʻi i ke ala a hoʻomālamalama.Ke hoʻohālikelike ʻia me kēlā mau "manaolana" i hiki ʻole a paʻakikī paha i ka hana nui, a i ʻole "nā mea huna" me nā kumu ʻike ʻole a me nā mea ʻai,ʻO Ganoderma lucidumtriterpenoids, hiki ke loaʻa i ka lōʻihi āu e makemake ai a ua hōʻiliʻili i ka ʻike hoʻohana no ka wā lōʻihi, pono e hoʻāʻo.

[Ke kumu] Wei Liu, et al.Ganoderma triterpenoids attenuate tumor angiogenesis i loko o ka maʻi maʻi ʻaʻai maʻi maʻi ʻaʻai ʻana i nā ʻiole olohelohe.Pharm Biol.2020: 58(1): 1061-1068.

HOPE

No ka mea kākau/ Ms. Wu Tingyao
Ua hōʻike ʻo Wu Tingyao i ka ʻike Ganoderma lima mua mai 1999. ʻO ia ka mea kākau oHoola me Ganoderma(i paʻi ʻia ma The People's Medical Publishing House ma ʻApelila 2017).
 
★ Ua paʻi ʻia kēia ʻatikala ma lalo o ka mana kūʻokoʻa o ka mea kākau.★ ʻAʻole hiki ke paʻi hou ʻia nā hana i luna, ʻokiʻoki a hoʻohana ʻia ma nā ʻano ʻē aʻe me ka ʻole o ka ʻae ʻia e ka mea kākau.★ No ka uhaki ʻana i ka ʻōlelo ma luna, e ʻimi ka mea kākau i nā kuleana pili kānāwai.★ Ua kākau ʻia ka kikokikona kumu o kēia ʻatikala ma ka ʻōlelo Pākē e Wu Tingyao a unuhi ʻia i ka ʻōlelo Pelekania e Alfred Liu.Inā loaʻa kekahi ʻokoʻa ma waena o ka unuhi (English) a me ka unuhi mua (Pake), e lanakila ka Pākē mua.Inā he nīnau ka poʻe heluhelu, e ʻoluʻolu e kelepona i ka mea kākau kumu, ʻo Ms. Wu Tingyao.